Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma von Papadopoulos, Nikolaos G., Szefler, Stanley J., Bacharier, Leonard B., Maspero, Jorge F., Domingo, Christian, Fiocchi, Alessandro, Lee, Jason K., Daizadeh, Nadia, Lederer, David J., Hardin, Megan, Gall, Rebecca, Djandji, Michel, Siddiqui, Shahid, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

Volltext

Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study von Tohda, Yuji, Nakamura, Yoichi, Fujisawa, Takao, Ebisawa, Motohiro, Msihid, Jerome, Djandji, Michel, Ortiz, Benjamin, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J., Ishida, Masato, Arima, Kazuhiko

Volltext

Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINU... von Bachert, Claus, Khan, Asif H., Lee, Stella E., Hopkins, Claire, Peters, Anju T., Fokkens, Wytske, Praestgaard, Amy, Radwan, Amr, Nash, Scott, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

Volltext

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils von Bleecker, Eugene R., Panettieri, Reynold A., Lugogo, Njira L., Corren, Jonathan, Daizadeh, Nadia, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J., Khodzhayev, Angela, Soler, Xavier, Ferro, Thomas J., Hansen, Christopher N.

Volltext

Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation von Busse, William W, Kraft, Monica, Rabe, Klaus F, Deniz, Yamo, Rowe, Paul J, Ruddy, Marcella, Castro, Mario

Volltext

Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the SINUS‐52 trial von Fokkens, Wytske J, Bachert, Claus, Hopkins, Claire, Marglani, Osama, Praestgaard, Amy, Nash, Scott, Deniz, Yamo, Rowe, Paul J, Sacks, Harry, Jacob‐Nara, Juby A

Volltext

Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose von Domingo, Christian, Rabe, Klaus F., Price, David, Brusselle, Guy, Wechsler, Michael E., Xia, Changming, Pandit-Abid, Nami, Gall, Rebecca, Rowe, Paul J., Deniz, Yamo, Jacob-Nara, Juby A., Radwan, Amr

Volltext

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma von Bacharier, Leonard B, Maspero, Jorge F, Katelaris, Constance H, Fiocchi, Alessandro G, Gagnon, Remi, de Mir, Ines, Jain, Neal, Sher, Lawrence D, Mao, Xuezhou, Liu, Dongfang, Zhang, Yi, Khan, Asif H, Kapoor, Upender, Khokhar, Faisal A, Rowe, Paul J, Deniz, Yamo, Ruddy, Marcella, Laws, Elizabeth, Patel, Naimish, Weinreich, David M, Yancopoulos, George D, Amin, Nikhil, Mannent, Leda P, Lederer, David J, Hardin, Megan

Volltext

Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design von De Prado Gomez, Lucia, Pavord, Ian, Busse, William, Brightling, Christopher E, Wechsler, Michael E, Rabe, Klaus F, Zhang, Mei, Xing, Jun, Jacob-Nara, Juby A, Rowe, Paul J

Volltext

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study von Wechsler, Michael E, Ford, Linda B, Maspero, Jorge F, Pavord, Ian D, Papi, Alberto, Bourdin, Arnaud, Watz, Henrik, Castro, Mario, Nenasheva, Natalia M, Tohda, Yuji, Langton, David, Cardona, Guido, Domingo, Christian, Park, Hae Sim, Chapman, Kenneth R, Mao, Xuezhou, Zhang, Yi, Khan, Asif H, Deniz, Yamo, Rowe, Paul J, Kapoor, Upender, Khokhar, Faisal A, Mannent, Leda P, Ruddy, Marcella, Laws, Elizabeth, Amin, Nikhil, Hardin, Megan

Volltext

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma von Corren, Jonathan, Katelaris, Constance H., Castro, Mario, Maspero, Jorge F., Humbert, Marc, Halpin, David M.G., Altincatal, Arman, Pandit-Abid, Nami, Soler, Xavier, Radwan, Amr, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

Volltext

AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps von Siddiqui, Shahid, Bachert, Claus, Chaker, Adam M, Han, Joseph K, Hellings, Peter W, Peters, Anju T, Heffler, Enrico, Kamat, Siddhesh, Zhang, Haixin, Nash, Scott, Khan, Asif H, De Prado Gomez, Lucia, Jacob-Nara, Juby A, Rowe, Paul J, Deniz, Yamo

Volltext

Examining the Role of Type 2 Inflammation in Eosinophilic Esophagitis von Chehade, Mirna, Falk, Gary W., Aceves, Seema, Lee, Jason K., Mehta, Vinay, Leung, John, Shumel, Brad, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J., Cunoosamy, Danen, Khodzhayev, Angela

Volltext

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA... von Busse, William W, Wenzel, Sally E, Casale, Thomas B, FitzGerald, J Mark, Rice, Megan S, Daizadeh, Nadia, Deniz, Yamo, Patel, Naimish, Harel, Sivan, Rowe, Paul J, Graham, Neil M H, O'Riordan, Thomas, Pavord, Ian D

Volltext

Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis von Wechsler, Michael E., Klion, Amy D., Paggiaro, Pierluigi, Nair, Parameswaran, Staumont-Salle, Delphine, Radwan, Amr, Johnson, Robert R., Kapoor, Upender, Khokhar, Faisal A., Daizadeh, Nadia, Chen, Zhen, Laws, Elizabeth, Ortiz, Benjamin, Jacob-Nara, Juby A., Mannent, Leda P., Rowe, Paul J., Deniz, Yamo

Volltext

Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook von Rabe, Klaus F, Rennard, Stephen, Martinez, Fernando J, Celli, Bartolome R, Singh, Dave, Papi, Alberto, Bafadhel, Mona, Heble, Jigna, Radwan, Amr, Soler, Xavier, Jacob Nara, Juby A, Deniz, Yamo, Rowe, Paul J

Volltext

Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial von Sher, Lawrence D, Wechsler, Michael E, Rabe, Klaus F, Maspero, Jorge F, Daizadeh, Nadia, Mao, Xuezhou, Ortiz, Benjamin, Mannent, Leda P, Laws, Elizabeth, Ruddy, Marcella, Pandit-Abid, Nami, Jacob-Nara, Juby A, Gall, Rebecca, Rowe, Paul J, Deniz, Yamo, Lederer, David J, Hardin, Megan

Volltext

Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP von Bachert, Claus, Khan, Asif H., Fokkens, Wytske J., Hopkins, Claire, Gevaert, Philippe, Han, Joseph K., Hellings, Peter W., Lee, Stella E., Msihid, Jérôme, Nash, Scott, Sacks, Harry, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

Volltext

Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma von Peters, Anju T., Sagara, Hironori, Corren, Jonathan, Domingo, Christian, Altincatal, Arman, Soler, Xavier, Pandit-Abid, Nami, Crikelair, Nora, Rowe, Paul J., Jacob-Nara, Juby A., Deniz, Yamo

Volltext

Dupilumab 200 mg was efficacious in children (6–11 years) with moderate‐to‐severe asthma for up to 2 years: EXCURSION open‐label extension study von Phipatanakul, Wanda, Vogelberg, Christian, Bacharier, Leonard B., Dell, Sharon, Altincatal, Arman, Gall, Rebecca, Ledanois, Oliver, Sacks, Harry, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

Volltext